View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Prilactone Next is replacing the spironolactone products Prilactone and Tempora, which will be discontinued.
Prilactone Next is available in three presentations of 10mg, 50mg and 100mg. It comes in easy-break, chewable tablets, designed to make it easier to give the required dose. The 10mg tablet has a two-way split for a dog between 2.5kg and 5kg, while the 50mg and 100mg tablets have a four-way patented clover-shaped design with the 50mg for dogs between 18.1kg and 25kg and 100mg for dogs between 37.6kg and 50kg.
Prilactone Next is available in boxes of three blisters of 10 tablets for the 10mg and 50mg presentations and three blisters of eight tablets for the 100mg presentation, for easy dispensing and storage in practice.
Nicola Barclay, product manager at Ceva Animal Health, said: "Prilactone Next is an improved, easy to administer spironolactone that enables owners to accurately treat their pets and will further enhance our existing cardiology range."
For further information, contact your local Ceva Animal Health territory manager.
The study “Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom” used the Small Animal Veterinary Surveillance Network to review electronic health records equating to 3,150,713 consultations (917,373 dogs) from 224 veterinary practices2.
Five hundred and seventeen cases were included. Dogs older than 6 years were excluded.
Of 321 dogs presented for a single seizure, seven (2.1%) were prescribed AEDs, which is in accordance with International Veterinary Epilepsy Task Force recommendations.
20% of the dogs in this group which had at least a 6-month follow-up, 20% did not have subsequent seizures recorded.
However, of 86 dogs which had suffered a seizure cluster at first presentation, only 38 (44%) were prescribe an AED, despite the task force recommendation that long term treatment in dogs with idiopathic epilepsy should be started immediately in the case of 2 or more seizures within 6 months, status epilepticus or a seizure cluster, severe post-ictal signs, or a deteriorating epileptic presentation.
Imepitoin was frequently selected in the treatment of cluster seizures despite no authorisation for this purpose.
Nicola Di Girolamo, Editor of JSAP said: “Studies like this one are instrumental to understand how primary care clinicians comply with current recommendations.
"Additional efforts may be required to fully adhere to the International Veterinary Epilepsy Task Force recommendations; being aware of these gaps is the first step towards improvement.”
References
CVS says there has been a steady increase in the number of clinicians offering peripatetic services on the premises of host practices in almost every area of clinical work, including surgery, cardiology, diagnostic imaging and dermatology. It's a model for improving patient access to more advanced levels of clinical care.
The company has appointed Ben Walton BVSc DSAS(Orth) MRCVS (pictured right), an RCVS Specialist in Small Animal Surgery (Orthopaedics) at Chestergates Veterinary Specialists, to head up the new network (called the Advanced Clinical Services Network, or ASCN). In a previous life, he offered a peripatetic surgery service in the North West of England and North Wales for several years.
Ben said: "I believe that the new network will deliver huge advantages to a number of stakeholders. The peripatetic model is an attractive proposition from a number of perspectives.
"For the host practices, is allows cases to be managed to a greater depth in-house, improving their service offering, and increasing opportunities for development of the practice team. It also allows the retention of revenue from these cases, which in turn justifies investment in facilities.
"For the client and patient, it improves the level of care that they receive at their home practice. Visiting clinicians bring expertise into practices through their own knowledge and experience, but also through development of the practice team, thus improving standards across the board."
Ben believes the model also offers better clinical career progression for experienced vets: "I believe that clinically-satisfying roles can be hard to come by at the moment.
"As a profession, we tend to be good at looking after our recent graduates. CVS, other large groups and independent practices have worked really hard on this over the last few years. There are also plenty of opportunities to develop your career on a management track, especially in the large groups.
"What there is a real lack of, though, are jobs that allow genuine clinical development. Many vets are well-supported to gain certificates and Advanced Practitioner status, but often there isn’t a satisfying caseload at the end of it.
"Within the new network, experienced vets will have a caseload that is predominantly or exclusively within their preferred discipline, and as they will be performing higher-value work than they would in a GP position, better remuneration packages will be justifiable. Ultimately, we want to be able reward experienced vets well, for doing a job that is clinically satisfying, and provides a valuable service to host practices and their clients."
CVS says it intends to develop the Advanced Clinical Services Network in multiple disciplines nationwide over the next few years.
Ben added: "Primarily, the ACSN is being established to service CVS practices, but we envisage that many of the services will also be available to non-CVS practices."
For more information, visit careerswithcvs.co.uk
Mr Ghinescu faced three charges:
Mr Ghinescu admitted the facts of charges 1 and 2 but denied that this rendered him unfit to practise as a veterinary surgeon, although Dr Ghinescu has had the status of a non-practising Member of the RCVS since May 2021.
Regarding Charge 3, Mr Ghinescu said that the failure to declare the conviction had been a genuine misunderstanding about whether he needed to declare a driving conviction as part of his annual renewal.
The Committee found that while his position was ‘plainly unreasonable of him and wrong’, it could not be sure beyond all reasonable doubt that his mistaken beliefs were genuine or not – therefore it found it not proven that he had been dishonest.
Nevertheless, it found that Mr Ghinescu had been misleading by failing to declare his convictions, even if unintentionally.
Having found Charges 1, 2 and part of Charge 3 proven, the Committee considered Mr Ghinescu’s fitness to practise, taking into account the part of the Code of Professional Conduct that says veterinary surgeons ‘must not engage in any activity or behaviour that would be likely to bring the profession into disrepute or undermine public confidence in the profession.’
It found that the convictions outlined in Charges 1 and 2 rendered him unfit to practise as a veterinary surgeon and that whilst Charge 3 demonstrated carelessness, it did not amount to serious professional misconduct.
Mitigating factors included having had no previous disciplinary history with the RCVS, admissions at both court and to the College and developing insight into his behaviour, with an acceptance he had acted shamefully and had no mitigation for his behaviour.
Hilary Lloyd, chairing the Committee and speaking on its behalf, said: “The Committee was of the view that the nature and seriousness of Mr Ghinescu’s behaviour, which led to the convictions, particularly the assault on his wife, was fundamentally incompatible with being registered as a veterinary surgeon.
"They are clearly serious offences as reflected in the prison sentence Mr Ghinescu was required to serve.
“There were two separate assaults on [his wife], one in the car and then a prolonged attack in the house, involving repeated punches to the face and kicks to the body, followed by threats to kill.
"The Committee considered this to be disgraceful conduct of the most grievous and reprehensible kind.
“The conduct represented a serious departure from professional standards; it was inexplicable, abhorrent behaviour, resulting in injuries to his wife.
"In light of these conclusions, the Committee decided that the only appropriate and proportionate sanction in this case was removal from the Register.”
Mr Ghinescu has 28 days from being informed of his removal from the Register to appeal the Committee’s decision.
www.rcvs.org.uk/disciplinary
The survey follows the launch last year of a new feature on VetSurgeon Jobs and VetNurse Jobs which allows employers to highlight the salary and benefits they offer. Specifically, the system allows practices to display a 'minimum offer', described to the job seeker as the starting point for a discussion, or a salary range.
Still, currently only 10% of job adverts on VetSurgeon.org and 16% on VetNurse.co.uk include the salary, despite some evidence that broadly speaking, advertising a salary can improve response rates.
But do veterinary job seekers want to see the salary advertised, and if so, how much of a different could it make? These are questions this survey seeks to answer.
My guess is that it may be more important to veterinary nurses than veterinary surgeons, because there is probably a greater variability in salaries amongst nurses, and more jobs where you'd struggle to pay the mortgage.
It'll be interesting to see.
To take part in the survey, which is completely anonymous, visit: https://www.surveygizmo.com/s3/5110214/Should-veterinary-salaries-be-advertised. It's 4 quick fire questions which should take you less than a minute.
VETNAPP offers a replacement to paper records and allows entry of drugs administered, physiological parameters (for example heart rate, respiratory rate and blood pressure) and complications occurring during an anaesthetic. The final anaesthetic chart can be converted to a PDF and attached to patient records.
Alastair said: "My motivation for creating the app was born of my frustration while working in Australia about how many handwritten anaesthetic records were incomplete and poorly filled in.
"I developed the app in partnership with an IT graduate at the University of Sydney. It is a replacement for paper records, with features such as you cannot move on to the next page until all data fields are complete. It also allows storage of thousands of records, therefore, allows easy retrieval of records, and prevents lost records which is common with paper records.
"I also would like to eventually have a cloud-based storage of data to allow anaesthesia studies such as drugs used, morbidity/mortality studies, to be carried out on a large scale basis, rather than single centre studies."
VETNAPP has been designed to meet the needs of both general practitioner veterinary surgeons and veterinary specialists in anaesthesia and analgesia.
At present, VETNAPP is only available for the iPad, priced at £59.99.
To download VETNAPP, go to: https://itunes.apple.com/gb/app/vetnapp/id980918731?mt=8.
The hearing proceeded in Ms Kay’s absence as she failed to attend. The Committee heard a number of charges relating to her practising while under the influence of alcohol, breaching undertakings to the College to abstain completely from alcohol, alleged serious clinical failings in relation to the treatment of two dogs, Izzy and Alfie, and making disparaging remarks to a client about other veterinary surgeons (the complete list of charges can be found on the College’s website: www.rcvs.org.uk/concerns/disciplinary-hearings/).
In relation to the first charge, (that in September 2016, while a locum veterinary surgeon at Haven Veterinary Surgeons Group, Great Yarmouth, she was under the influence of alcohol), the Committee heard from a veterinary nurse at the practice who told how on different occasions Miss Kay had appeared to need more assistance than expected, was overly friendly in speaking to clients, was unable to prepare a syringe correctly, and finally, on 14 September 2016, was found asleep in the car with an open can of alcohol by her feet. The Committee also heard from a number of other witnesses from the Haven Veterinary Surgeons Group who also provided evidence of Ms Kay’s behaviour on the day in question. Following deliberations, the Committee found the first charge to be proved.
The second charge related to the breaching of undertakings which Ms Kay had given to the College to the effect that she would abstain completely from alcohol. When samples were taken on 3 August 2017, however, it was found that she had been consuming alcohol in the recent past. The Committee was therefore satisfied that the second charge was proved.
The Committee then turned to the third charge, that in March 2017 Ms Kay had displayed a number of clinical failings when performing surgery on a cocker spaniel, Izzy, belonging to Mrs Debbie Coe. The Committee found the majority of the charges proved, amongst others that she failed to obtain informed consent for surgery, performed surgery in her own home when it was not registered as a veterinary practice and it was not possible to ensure sterility, and that she failed to provide suitable post-operative analgesia to Izzy.
The College then turned to the fourth charge, which concerned her treatment of Mrs Coe’s other dog, Alfie, a Miniature Schnauzer. The charge was that in March 2017, Ms Kay euthanased Alfie in an inappropriate manner, and used a controlled drug without having a registered veterinary premise from which to dispense it. After hearing from an expert witness the Committee found the charges proved.
Finally, the Committee heard evidence relating to the fifth charge, namely that in or around July 2016, Ms Kay made disparaging remarks to Mrs Coe about other veterinary surgeons who had treated Alfie, and that between 17 March and 31 March 2017 she had sent inappropriate texts and voicemail messages to Mrs Coe about the treatment of her dogs and payments owed in relation to this. The Committee thought there was not enough evidence in relation to the voicemails, but found the remainder of the charge proved.
Taking all into account, the Committee found that Ms Kay’s conduct had fallen far short of the standard expected of a member of the veterinary profession and concluded that her conduct clearly amounts to disgraceful conduct in a professional respect.
Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considered that the only appropriate sanction is that of removal from the Register. Such a sanction is required to protect animals and to send a clear message to the Respondent, and to all veterinary surgeons, of the unacceptability of the conduct identified in this case. Such conduct undermines public confidence in the profession and fails to uphold proper standards of conduct and behaviour.
"Accordingly, the Committee has decided that removal from the Register is the only appropriate and proportionate sanction in this case."
Ms Kay has 28 days from being informed about the Disciplinary Committee’s decision to make an appeal to the Privy Council.
Dr Berwyn Clarke, CEO of PBD Biotech, which developed the bacteriophage-based detection method, says this is significant step forward: "In situations where a farm has had an ongoing chronic bovine TB problem, APHA’s protocol offers a promising new approach to controlling the infection.
"Actiphage is now included within a series of measures that farmers can use in conjunction with their vet and with specific APHA approval as a means to improving their disease management strategy.
"For many farms that have been struggling for years it provides the first step to becoming TB free. This move by the APHA is a really positive step towards tackling this devastating disease."
Much of this new strategy, as part of a private TB eradication plan, has been driven by the success of Devon-based vet Dick Sibley, who incorporated Actiphage into a disease management strategy last Autumn to help clear a dairy herd that had been stricken with TB since 2012.
Dick said: "The approach of directly measuring the presence of live bacteria in the blood in just six hours is a totally different but complementary measurement to other technologies and has enabled enhanced testing, early detection and containment of the infected animals.
"We don’t have all of the answers yet, but it’s about predicting, preventing and managing what we can – and Actiphage has contributed greatly to the outcome we’ve been after for so long."
The Exceptional private use of non-validated tests for TB on cattle in England protocol enables any private veterinary surgeon to request APHA permission for exceptional use of Actiphage and the other non-validated tests, subject to certain criteria that include herd supplementary interferon-γ (IFN- γ) testing, discussions with the APHA Case Vet and the farmer’s written consent.
Berwyn added: "Actiphage is unique in directly detecting live mycobacteria in blood or milk, and it can also distinguish between a vaccinated and an infected animal - paving the way for new types of disease control when vaccines become available in the future.
"We are working with international governments, and the test is being trialled on bovine, ovine as well as exotic species, but we appreciate it is new to the UK market so we’re keen to answer any queries vets or farmers may have."
The new test will be profiled in the Innovation Hub at the Royal Norfolk Agricultural Show next month (27 & 28 June).
PBD Biotech says Actiphage will require further testing before it is officially approved for standard veterinary use in the UK, however under the APHA protocol it is now permitted for private use where herds have experienced persistent breakdowns and this will contribute to the evidence-base required for official validation by the OIE and acceptance by APHA.
Within this protocol, APHA has outlined a number of other non-validated tests that may be proposed for exceptional use in cattle herds with chronic breakdowns, including: the Actiphage assay, developed by PBD Biotech and Nottingham University; the Enferplex TB serological test, produced by Enfer Laboratories Ireland and approved in GB for use in camelids; and the Polymerase Chain Reaction (PCR) testing of faecal samples. APHA says this is not an exhaustive list and that the protocol covers any current or future non-validated tests for bovine TB.
The comparative intradermal tuberculin skin test and the IFN- γ blood test remain the only ante mortem tests currently approved for the statutory cattle TB testing programme in Great Britain.
The full Exceptional private use of non-validated tests for TB on cattle in England is available on the APHA Vet Gateway: apha.defra.gov.uk/vet-gateway/non-valid-tb-testing
Suvaxyn PRRS MLV offers the earliest piglet vaccination from the first day of age, securing immunity before the risk period which lasts until the end of the fattening. Pig protection is established 28 days after vaccination, and lasts for 26 weeks after vaccination in fattening pigs, and 16 weeks after vaccination in gilts and sows. Zoetis says the vaccine reduces viremia and nasal shedding of the virus.
Monica Balasch, Associate Director, Global Biologicals Development at Zoetis said: "In Europe, Porcine Reproductive and Respiratory Syndrome is known for severe impacts on reproduction including lowering birth rates, increasing abortion, stillbirth, mummified, as well as weak live-born piglets, and death.
"In clinical studies conducted with Suvaxyn PRRS MLV, we found excellent results vaccinating pigs from the first day of age. It is safe to be used as the earliest protection in piglets, and to protect the whole herd against PRRS, as it is also safe for use in gilts and sows.
"The new vaccine represents a flexible alternative to allow for new customized PRRS control programs developed by veterinarians for producers."
Alvaro Aldaz, Director, Commercial Development and Innovation, Swine, at Zoetis said: "We are excited to bring this innovative vaccine to Europe. Suvaxyn PRRS MLV has been developed using a very innovative vaccine technology which brings swine veterinarians a new advanced PRRS control tool.
"As well reducing viremia, nasal shedding and lung lesions in fattening pigs, the vaccine has been proven to overcome maternal immunity, which increases the efficacy of the vaccine when given to piglets during the first days of life. Additionally, it allows veterinarians for use PRRS mass vaccination within the claim; mass vaccination has become more and more popular in several European countries."
Suvaxyn PRRS MLV is a veterinary vaccine that contains a European PRRS virus strain (Genotype 1) that has been grown and attenuated in a uniquely modified cell line developed by Zoetis.
Jay Calvert, Research Director, VMRD Global Biologicals Research at Zoetis said: "Suvaxyn PRRS MLV is safe based on true loss of virulence, and not based on a temporary reduction in ability to replicate in macrophage cells in the lung of the pig."
Zoetis says the efficacy of Suvaxyn PRRS MLV is supported by a comprehensive program of clinical studies reviewed by the European Medicines Agency and included in the regulatory procedure approved by the European Commission in August 2017.
The European public assessment report is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/004276/WC500235212.pdf
The company says the most common side effects with Suvaxyn PRRS MLV (which may affect more than one in 10 pigs) are a short-lived increase in body temperature (0.5°C on average and up to 1.4°C individually) within four days of vaccination, and in sows local reactions in the form of swellings which resolve without treatment within five to 32 days.
The new maternity policy will offer enhancement at 100% of full pay for 10 weeks, and 50% of full pay for a further 10 weeks, without any clawback provision should mothers decide not to return to CVS after their leave.
As part of the Time To Change Pledge, CVS will submit a plan for introducing evidence-based interventions and policy to help its employees work in ways that promote positive mental wellbeing.
CVS's plan includes the appointment of 250 Wellbeing Champions who will be trained in first aid for mental health. The company also plans to roll out further training on managing stress and mental health issues for line managers in 2020.
Richard, pictured right, said: "We are proud to be the first major veterinary employer to sign the Time to Change Pledge. The CVS wellbeing working party have made much progress in the last 12 months delivering our plan which has been formalised through participating in the Time to Change pledge.
"We recognise that the pressures in our industry are significant and unique, and that there’s more work to do. We remain committed as a company and wellbeing working party to changing the way we all think and act about mental health in the workplace for the better."
Betafuse contains 5mg/g fusidic acid and 1mg/g betamethasone gel. It is available in 15g and 30g polyfoil tubes, designed to reduce the likelihood of splitting and loss of product during use.
Richard Palmer, Global Head of Sales and Marketing at Norbrook said: "We are delighted to be bringing this new product to the market in 16 European countries including the UK and Ireland. Betafuse is particularly exciting for us as we have improved the packaging and we have extended the 'in use' shelf life to eight weeks in comparison to six weeks for the pharmaceutically equivalent pioneer.
"This continued investment in our companion animal portfolio comes on the back of our recent launch in the US of Carprofen Chewable Tablets, an anti-inflammatory also for dogs. Our £40 million multi-year investment programme which we are currently engaged in, includes a significant emphasis on new product development including investment in R&D and our facilities infrastructure."
Lizzie Barnard, UK Product Manager added: "Betafuse offers the prescribing veterinary surgeon greater choice and it complements our existing companion animal skin care portfolio which includes Marbodex, a treatment for otitis externa in dogs.
"“Product support material is available and includes a guide for dog owners on how to apply Betafuse simply and effectively. This leaflet is available by contacting your territory manager or by downloading it from our website."
For more information, visit: https://www.norbrook.com/
The centre was launched in February last year after an 8-month briefing and design period, followed by a 9-month construction and fit-out process.
Paragon and DesM also picked up the top prize in the Conversion category, awarded to practices which have made use of buildings previously used for other purposes.
John Marsh said: "Our aim was to build on our experience with two previous small animal hospitals for the RVC and Lower Langford Veterinary School, in designing a 'practitioners' answer' to veterinary care, but adapted to a more commercial facility, mindful of a practical but bright working environment for both the clinicians and owners, where it is a pleasure to work and a catalyst for enabling the best possible animal care."
Paragon managing director Ian Monteith said: "Every year, the BVHA seeks out and rewards the very best veterinary hospitals across the UK and we are delighted the high standards we set here at Paragon have been recognised.
"This is a terrific compliment to the very careful planning that went into designing the building and equipping it with the very latest equipment and technology."
In their report, the BVHA assessor said: "The premises are spectacular in design and appearance, creating an immediate impression of clinical excellence and quality patient care to both clients and visiting clinicians.
"The quality of the clinical work being undertaken was easy to see. There was a very positive attitude to training and induction routines, as well as mental health and team welfare."
There was one other category, for the best refurbishment, which was won by Vets Now’s hospital in Glasgow.
Bonqat 50 mg/ml oral solution for cats contains pregabalin, an analgesic, anti-epileptic which has now been licensed for the alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.
Tessie 0.3 mg/ml oral solution for dogs contains tasipimidine and is licensed for the short-term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.
Dômes Pharma points to research which shows that in the UK 1.4 million1 dogs show signs of distress when left alone, and 4.4 million dogs1 show fear of loud noises.
In addition, over 4 million cats2 are not having routine vet checkups each year, with 26%2 of these owners reporting that it is too stressful for their cat or themselves.
Jonathan Hill, UK country manager at Dômes Pharma sid: "Dômes Pharma is excited to be launching two new innovative products to help vets manage cases in this complex area.
"These products expand our portfolio and provide essential options for owners and their pets struggling with these situational related problems."
https://www.tvm-uk.com/the-behavioural-range
Reference
With fewer than 72 female Suffolk Punches remaining in the UK and fewer than 300 in the world, every female born is vital to the survival of this endangered British horse.
In 2019 Tullis Matson, owner and managing director of Stallion AI Services, saw an opportunity to use a new technological advancement in the sex sorting of equine semen to provide a lifeline to Britain’s critically endangered rare and native horses.
Tullis said: “To be able to use our reproduction expertise in this way, to help preserve an irreplaceable part of our magnificent heavy horse heritage is something we have been working towards for many years. The challenges have been great and many, but watching the birth of this beautiful, healthy filly foal was a truly magical experience."
The sex sorting project uses specialist equipment to sex sort the semen prior to insemination based on the difference in DNA content between X and Y bearing spermatozoa.
Ruby, the Suffolk Punch mare and Holbeach Iggy, the Suffolk stallion were selected and matched based on their genetics as part of a project between The Rare Breed Survival Trust and Nottingham Trent University that uses pedigree information to enable the breeding of small populations in a way that minimises the risk of inbreeding and genetic decline.
Christopher Price, Chief Executive of the Rare Breed Survival Trust, said: “This is tremendous news for anyone concerned with the conservation of our native equines. The most effective way of increasing the population size of this very rare breed is by increasing the number of fillies being born.
“The project demonstrates the viability of using new techniques for selecting female foals in order to increase the breeding population much more rapidly than could be achieved through relying on traditional methods. We hope it will prove to be a model for more projects in the future.”
The study1, which was conducted by surgery resident Dr Charlie Brincin at Highcroft Veterinary Group (soon to be Bristol Vet Specialists) and orthopaedic surgeon Dr Matt Matiasovic at Manchester Vet Specialists, looked at the records of 825 dogs that had been treated surgically for unilateral MPL at 10 referral centres, and then had a planned follow-up visit, including radiographs.
The frequency of, and reasons for, changes in further recovery recommendations were investigated.
The findings demonstrated that if the dog made an uneventful2 recovery after surgery, was presented without owner concern, and if no abnormality was found on physical examination, then radiographic findings only led to a change in recommendation in 3% (13/432) of these dogs.
Researchers say that this reflects similar research on the influence of follow-up radiographs in human medicine, and those of previous veterinary studies on post-operative radiographs, following uncomplicated tibial plateau leveling osteotomy (TPLO). These particular studies3,4 showed radiography had an impact on post-operative management in just 2%-3.8% of cases.
As a result of the MPL and TPLO studies, Highcroft Veterinary Referrals and Manchester Veterinary Specialists will no longer systematically perform follow-up radiographs on their patients, unless justified clinically.
Charlie said: “Radiographs are not without additional costs or risks - including radiation exposure, sedation-associated risks and strain on veterinary staff.
"Radiographic intervention should be clinically justified and our study suggests that if the dog had an uneventful recovery and is presented without owner or clinician raised concern, then repeat radiographs might not be necessary.
"This study also highlights the value of a thorough owner history and clinical examination for clinical decision-making when re-examining dogs following this orthopaedic surgery.”
The MPL study also evaluated factors which significantly increased the risk of finding radiographic abnormalities at routine follow-up, and those which led to a change in post-operative recommendation.
Lameness, administration of analgesia at follow-up, and history of unplanned visits prior to routine re-examination were associated with increased odds of a change in postoperative plan (P < 0.001).
In the absence of owner and clinician concerns, the odds of having a change in convalescence plans were not different, whether or not isolated radiographic abnormalities were present (P = 0.641).
According to a report in the Daily Mail, Worcester vet David Denny MRCVS accidentally euthanised a Jack Russell in the presence of its owner, who believed he was giving the animal antibiotics.
Mr Denny told VetSurgeon.org that it had been the result of a dreadful misunderstanding between himself and his secretary, for which he had apologised, but that he couldn't say much more because the VDS had advised him not to talk to the media.
The dog, called Gunner, was 14 years old; old enough that alarm bells obviously didn't go off when it was presented to Mr Denny for euthanasia (or so he thought).
The story does serve as a reminder of the importance of communicating with absolute clarity, both written and oral, when performing euthanasia. In this case, the Daily Mail reports that Mr Denny asked the client: "if Gunner had had enough". Under any other circumstances, that would seem a sensitive comment to make. In this case, though, the owner thought he meant the dog had had enough of its cough.
Mr Wood was removed from the Register in 2018 after being convicted of posessing indecent images of children and made subject to a Sexual Harm Prevention Order for five years.
Mr Wood first applied to rejoin the Register in 2020 but his application was rejected.
At the outset of his second application last month, Mr Wood’s counsel argued that he is professionally competent to be restored, that he had strong mitigation for his offending, that he had consistently and repeatedly expressed and demonstrated profound remorse, that he posed a low risk of re-offending, that he had proactively engaged with the Probation Service and voluntary counselling to gain further insight into his offending, and that he had completed his community sentence and was no longer subject to any of the court orders arising from his conviction.
The Committee then weighed up whether Mr Wood had accepted its original findings in 2018, the seriousness of the offences, whether he demonstrated insight, protection of the public and the public interest, the future welfare of animals should he be restored to the Register, the length of time off the Register, Mr Wood's conduct since he was removed and evidence that he had kept up-to-date with veterinary knowledge, skills and practice.
Dr Kathryn Peaty MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee is satisfied that Mr Wood has done everything required of him in order to be able to satisfy the Committee that he is fit to be restored to the Register.
“At the last application in June 2020, he was unsuccessful largely because of the outstanding ancillary Court Orders that did not conclude until early 2023. Those Orders have now concluded
“He has shown significant insight into his offending behaviour. He has been proactive in his rehabilitation and taken significant steps to ensure there would be no repetition.
“He has a small, but strong, network of people around him who appear to genuinely care about him and support him. He has worked hard at maintaining his skills and knowledge, in so far as he has been able to in light of not being able to practise as a veterinary surgeon.
“He is thoughtful and realistic about his prospects going forward. His responses to questions about addiction were appropriate and persuasive. He has expressed genuine remorse and there is, in the Committee’s view, a public interest in allowing him to be restored to the Register.”
For the research, Miele commissioned independent market research firm Sapio to interview 1000 pet owners and 100 UK-based vet practices.
Veterinary practices have good reason to worry about complaints: the research showed that 89% of veterinary clients would be quick to tell others if they were dissatisfied with any aspect of the practice or care received. 63% said they would air their grievances on an online review site and 60% said they'd share their views on social media.
Those figures appear to be borne out by the fact that only 10% of vets said they had not seen any negative comments online about their practice.
Interviews with pet owners also found that the top five factors to affect a practice's reputation were: standard of care, a clean and hygienic environment, good customer service, the cost of treatment and waiting times, in that order.
64% of vets agreed that practice hygiene has become increasingly important with cleanliness of staff uniforms and waiting rooms among the first things that customers notice.
The suitably spruce Sam Bailey (pictured right), Sales & Marketing Director for the Professional division of Miele said: "Vet practices are increasingly coming under the same online scrutiny as hotels and restaurants and are being judged on everything from customer service through to staff appearance and waiting times.
"As our research results show, vets are already concerned about their reputations and it’s not just customer service and care outcomes that matter to pet owners, they also have high expectations when it comes to the practice environment too and are looking at cleanliness, hygiene and staff appearance.
"Through our network of approved partners we are working with more and more vet practices throughout the UK to ensure their on premise laundries not only meet WRAS regulations but also support their standards on hygiene, infection control and cleanliness."
Using practices developed for human healthcare measurement, NewMetrica developed VetMetrica, which the company says can measure how an animal “feels” about its circumstances from its individual perspective.
Jim Brick, Vice President Commercial Development and Lifecycle and Innovation at Zoetis said: "This novel approach supports a significant shift in veterinary care and animal welfare more generally towards the attainment of good or excellent quality of life in companion animals.
"The benefits of NewMetrica’s digital instruments have been validated through scientific publications and the FDA, and the EMA has confirmed the algorithms that produce the results.”
Jamie Brannan, President International Operations, Zoetis added: "We expect NewMetrica’s tools and algorithms to support earlier detection and treatment of diseases as we gain more insight into the quality of life of our pets and be an important element of future product development.
“NewMetrica’s instruments will give us scientifically validated results for alleviation of OA pain that veterinarians and pet owners will appreciate and value.”
https://www.newmetrica.com
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
AB Science, a young Paris-based biotech company, has announced the pan-European commercial launch of its veterinary anticancer drug, Masivet
Masivet was approved in November 2008 by the European Medicines Agency (EMEA) for the treatment of dogs with non-resectable grade 2 or 3 mast cell tumours. Masivet's active pharmaceutical ingredient is masitinib, a tyrosine kinase inhibitor. Masitinib, discovered and developed by AB Science, belongs to a therapeutic class of drug known as targeted therapy that is, according to AB Science, revolutionising the treatment of cancer in humans.
Alain Moussy, CEO of AB Science said: "Masivet is the first product ever registered as a cancer treatment in veterinary medicine. AB Science is a dynamic and very entrepreneurial biotech company, and is proud to have introduced a drug that can extend the life of dogs suffering from cancer ahead of the large pharmaceutical companies".
The company says Mastocytoma can be an aggressive cancer with a poor prognosis, and represents up to 20% of all cutaneous canine tumours. Some breeds are particularly susceptible, among them Golden Retrievers, Labradors and Boxers. Cancers have the same prevalence in dogs as in humans (1 dog in 4 will suffer from cancer during its lifetime) but surprisingly, no drugs developed for veterinary medicine with a demonstrated efficacy and safety have ever been approved until the arrival of Masivet.
The company claims two main benefits of the new treatment:
AB Science is a biotech company specialising in developing targeted drugs for high need indications, such as cancers, chronic inflammatory diseases and neurodegenerative disorders. Masitinib is the most advanced drug in the pipeline. Now being marketed in veterinary medicine, masitinib is also under development in humans, with phase 3 clinical studies in pancreatic cancer and in gastrointestinal stromal tumour (GIST).
Alain Moussy said: "This registration in veterinary medicine is good news for the future success of masitinib in humans, for whom we are aggressively developing it in cancers and other indications with high morbidity or pain.
"It is very unusual to develop such an innovative product simultaneously in veterinary and human medicines, and even more so that the product is registered in veterinary medicine first. There is no doubt that experts in human oncology will be watching Masivet's future very closely from now on.. However, people will have to wait a while before benefiting from masitinib because it is unlikely to be available to man before 2012".
For more information, see www.masivet.com and www.ab-science.com
Hot on the heels of Eurovet, Ceva Animal Health has launched Emeprid, containing the anti-emetic and pro-kinetic metoclopramide. Emeprid is licensed in cats and dogs for the symptomatic treatment of vomiting and reduced gastro-intestinal motility associated with gastritis, pyloric spasm, chronic nephritis and digestive intolerance to some drugs.
There are two formulations available; a 10ml multi-dose vial containing 5mg/ml metoclopramide for IV, SC or IM injection and a 125ml 'sweet orange and apricot flavoured' oral solution containing 1mg/ml metoclopramide. They are priced at £7.99 for the 10ml injectable bottle and £9.99 for the oral solution.
For further information, please contact your Ceva Animal Health representative or call the veterinary support team on 01494 781510.
The Vital Support launch includes a new Feline Renal Multipack to support cats with chronic kidney disease and loss of appetite. The multipack contains four wet pouches with different aromatic profiles to help stimulate decreased appetite and deliver optimum food acceptance and compliance. Multipacks will be available from October 2020.
Royal Canin has also introduced new Early Renal diets to help support the kidneys at early stages of renal insufficiency, and will be discontinuing its Feline VCN Senior Consult Stage 2 diets.
The company is also introducing two new diets for small dogs: Renal Small Dogs to support small breed dogs in the more advanced stages of chronic renal insufficiency, and Mobility C2P+ Small Dogs, formulated to support healthy joint function.
Other changes include a switch to 100% sustainably sourced salmon in its renal wet pouches, and to vegetable sources of glucosamine, instead of shellfish.
For more information, visit: https://vetportal.royalcanin.co.uk, speak to a member of the veterinary pillar team or contact the Nutritional Helpline.
For its research, the company surveyed 700 veterinary veterinary professionals.
The subsequent report, "Digital Adoption in Veterinary Medicine", provides up-to-date data on the levels of digital adoption by vets in the UK.
It also explores their attitudes to technology and digital communications tools, and the barriers to adoption. At the Zoom meeting, Scott Goodsir-Smyth, Provet Cloud’s VP of Growth for the UK & US will share and discuss some of the main findings of the report. He will also be answering questions about how practices can go digital, what the pitfalls are, how you can get the most value out of practice management software, and whether you should switch to the cloud. With the RCVS currently in the process of changing the rules regarding telemedicine, and only 23% of veterinary practices currently using telemedicine, this meeting could not be more timely. VetSurgeon.org and Provet are now inviting questions from vets about adopting digital technology, including online booking, integrated payments, pet owner apps, telemedicine, referral portals and digital whiteboards. The people who submit the best ten questions will be able to ask them before anyone else on the night and the best of the lot will get a bottle of champagne in time for Christmas.
To download the report, visit: https://www.provet.cloud/provet-cloud-digital-adoption-report To submit your question, email it to editor@vetsurgeon.org by Wednesday 9th November at 11:00am.
To register to join the Zoom meeting, visit: https://us06web.zoom.us/meeting/register/tZIsdOugpzMoGd0mrFcC_cyz1kNrGcwpMULV
Mr Gove ministerial statement followed the brouhaha last week when MP's voted against transferring the EU protocol on animal sentience into UK law.
However, Conservative MP Zac Goldsmith said in a tweet that the vote had not been about whether or not MPs recognise animals as sentient, but about the best legal framework within which to deliver high standards of animal welfare. Rachel Maclean, MP for Redditch also weighed in, saying that the idea that MPs had voted against animals as sentient beings was 'fake news'.
Mr Gove's ministerial statement reads as follows:
"This Government is committed to the very highest standards of animal welfare. As the Prime Minister has set out, we will make the United Kingdom a world leader in the care and protection of animals.
It has been suggested that the vote last week on New Clause 30 of the EU Withdrawal Bill somehow signalled a weakening in the protection of animals - that is wrong. Voting against the amendment was not a vote against the idea that animals are sentient and feel pain - that is a misconception.
Ministers explained on the floor of the house that this Government’s policies on animal welfare are driven by our recognition that animals are indeed sentient beings and we are acting energetically to reduce the risk of harm to animals – whether on farms or in the wild. The vote against New Clause 30 was the rejection of a faulty amendment, which would not have achieved its stated aims of providing appropriate protection for animals.
The Prime Minister has made clear that we will strengthen our animal welfare rules. This government will ensure that any necessary changes required to UK law are made in a rigorous and comprehensive way to ensure animal sentience is recognised after we leave the EU. The Withdrawal Bill is not the right place to address this, however we are considering the right legislative vehicle.
We are already proposing primary legislation to increase maximum sentences for animal cruelty from six months to five years, and the creation of a new statutory, independent body to uphold environmental standards.
The current EU instrument – Article 13 – has not delivered the progress we want to see. It does not have direct effect in law – in practice its effect is very unclear and it has failed to prevent practices across the EU which are cruel and painful to animals.
In contrast, here in the UK, we are improving animal welfare standards without EU input and beyond the scope of Article 13. We are making CCTV mandatory in all slaughterhouses – a requirement which goes above and beyond any EU rule. We will consult on draft legislation to jail animal abusers for up to five years – more than almost every other European nation. We propose combatting elephant poaching with a ban on the ivory trade which is more comprehensive than anywhere else in Europe. Our ban on microbeads which harm marine animals has been welcomed by Greenpeace as “the strongest in the world”, and is certainly the strongest in Europe.
Once we have left the EU there is even more we could do. EU rules prevent us from restricting or banning the live export of animals for slaughter. EU rules also restrict us from cracking down on puppy smuggling or banning the import of puppies under 6 months. Article 13 has not stopped any of these practices – but leaving the EU gives us the chance to do much better. We hope to say more in these areas next year.
This government will continue to promote and enhance animal welfare, both now and after we have left the EU."
Photo: Curious cattle on farmland in Cornwall UK. Shzphoto/Shutterstock